HOME >> BIOLOGY >> NEWS
Hepatitis B drug can compromise HIV treatment

Treating hepatitis B patients with the drug entecavir can cause those who are also infected with HIV to become resistant to two of the most important drugs in the anti-HIV arsenal, according to a new report in the New England Journal of Medicine.

In findings published June 21, 2007, online in the journal, the researchers reported that a patient infected with both hepatitis B and HIV who was treated with entecavir developed a mutant strain of HIV that is resistant to the antiviral drugs lamivudine and emtricitabine. Entecavir is manufactured by Bristol-Myers Squibb and is marketed under the trade name Baraclude.

The research team was led by Chloe Thio and Howard Hughes Medical Institute investigator Robert Siliciano, both at The Johns Hopkins University School of Medicine. The analyses reported in the paper were performed by lead authors Moira McMahon, Benjamin Jilek, and Timothy Brennan in the Siliciano laboratory.

The groups initial report of the findings in February, 2007, at the Conference on Retroviruses and Opportunistic Infections led the drugs manufacturer, Bristol-Myers Squibb, to change its product labeling to warn of the potential for HIV drug resistance, notify prescribing physicians, and inform the Food and Drug Administration. The United States Department of Health and Human Services now recommends against using entecavir as the first option in treating hepatitis B in co-infected patients who are not already using drugs to suppress HIV. More than 4 million people worldwide are believed to be infected with both viruses.

The scientists emphasized that finding drug resistance in this setting underscores the need to test all antiviral drugs for anti-HIV activity before they are approved for use.

Entecavir is a chemically altered version of a chemical called a nucleoside. The drug blocks viral replication by plugging itself into a polymerase enzyme in the hepatitis B virus that helps produce new viral DNA
'"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
20-Jun-2007


Page: 1 2 3

Related biology news :

1. Hepatitis C helicase unwinds DNA in a spring-loaded, 3-step process
2. Hepatitis E takes a piggyback
3. New hope for Hepatitis C research
4. Hepatitis C therapy: Inhibiting newly discovered microDNA molecule
5. New insights into protein synthesis and Hepatitis C infections
6. Hepatitis B accounts for 40 percent of missing Asian women
7. Hepatitis C complicated by morphine withdrawal
8. Identification of a protein important for Hepatitis B replication
9. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
10. Hepatitis C virus linked to non-Hodgkins lymphoma
11. Group decisions: From compromise to leadership in pigeon homing

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2020)... (PRWEB) , ... February 11, ... ... dedicated to solving complex problems for life sciences companies and government agencies, ... 30 years of management consulting expertise to Tunnell, with significant experience assessing, ...
(Date:2/6/2020)... ... 06, 2020 , ... Kerafast Inc. , developers of ... announced an agreement with The Good Food Institute , a nonprofit organization ... partnership, terrestrial meat and aquatic cell lines will be made available to scientists ...
(Date:1/29/2020)... , ... January 29, 2020 , ... ... the new Analytics and Data Sciences practice, providing consulting services for strategy, research ... was announced by Mike Townley, co-founder and Managing Partner of CREO, an innovative ...
Breaking Biology News(10 mins):
(Date:1/22/2020)... ... 21, 2020 , ... Microbial Discovery Group LLC (MDG) is ... and Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners with ... 30 years of sales experience working across multiple different market sectors such as; ...
(Date:1/10/2020)... ... January 09, 2020 , ... A new report from ... vendor qualification process, a critical element of clinical trial set up and execution. ... vendor qualification process creates delays in initiation in 7% of clinical trials for ...
(Date:1/8/2020)... SHREWSBURY, Mass. (PRWEB) , ... January 08, 2020 ... ... engineered clad metal wire composites that can achieve specific properties for use in ... Composite Clad Metal Wire combines up to three metals or alloys to ...
(Date:1/7/2020)... N.J. (PRWEB) , ... January 07, 2020 , ... Vuja ... prevent cancer progression and recurrence, today announced the appointments of Chand Khanna, DVM, PhD, ... Co-founder and CEO of Vuja De said, “We are delighted to welcome Chand and ...
Breaking Biology Technology:
Cached News: